Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart
Chemical Biology & Drug Design · 2023-11 · 102 (5) · 1085-1096
DOI: 10.1111/cbdd.14308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 02.08.2023. Verfasst von Züleyha Doğanyiğit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Histology and Embryology, Yozgat Bozok University, Yozgat, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Bozok Üniversitesi.
Abstract (Originalsprache)
The aim of this study is to reveal the effects of the use of linagliptin, a DPP‐4 inhibitor due to its beneficial cardiovascular effects, on endoplasmic reticulum stress (ERS) signaling, which is involved in the pathogenesis of cardiovascular complications related to type 1 diabetes. BALB/c female mice ( n = 72) were divided into six groups: control, diabetes+insulin, diabetes+linagliptin, diabetes+linagliptin+insulin, diabetes+TUDCA, and diabetes+TUDCA+insulin. Immunohistochemistry and western blot method, qRT‐PCR, ELISA method, and malondialdehyde (MDA) measurements were performed. Linagliptin administered to the type 1 diabetic mouse heart significantly reduced the expression levels of the total and cleaved forms of ATF6, ATF4, and p‐JNK, caspase 3. Immunohistochemical and western blot analyses revealed that cleaved caspase 3 protein expression was significantly increased in the diabetes+insulin group compared to the other groups. According to ELISA findings, TUDCA was more effective in reducing NOX 1 and MDA levels than linagliptin. While linagliptin decreased the Chop mRNA level, no change was observed in the Grp78 mRNA level. Our findings showed that there was not much difference between the administration of linagliptin alone or in combination with insulin. Our study reveals that linagliptin is an effective therapeutic agent on ERS and apoptotic UPR in type 1 diabetic hearts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Histology and Embryology, Yozgat Bozok University, Yozgat, Turkey.
- Faculty of Medicine, Department of Medical Biology, Erciyes University, Kayseri, Turkey.
- Faculty of International Medicine, Department of Biophysics, University of Health Sciences, Istanbul, Turkey.
- Faculty of Medicine, Department of Histology and Embryology, Akdeniz University, Antalya, Turkey.
ORCID-Profile: Züleyha Doğanyiğit
Förderung
- Bozok Üniversitesi
Zitieren
APA
Doğanyiğit, Z., Okan, A., Taheri, S., Yılmaz, Z., Akyüz, E., & Demir, N. (2023). Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart. Chemical Biology & Drug Design, 102(5), 1085-1096. https://doi.org/10.1111/cbdd.14308
Vancouver
Doğanyiğit Z, Okan A, Taheri S, Yılmaz Z, Akyüz E, Demir N. Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart. Chemical Biology & Drug Design. 2023;102(5):1085-1096. doi:10.1111/cbdd.14308
BibTeX
@article{Doanyiit2023,
author = {Doğanyiğit, Züleyha and Okan, Aslı and Taheri, Serpil and Yılmaz, Zeynep and Akyüz, Enes and Demir, Necdet},
title = {Evaluation of linagliptin and insulin combined therapy on unfolded protein response in type 1 diabetic mouse heart},
journal = {Chemical Biology & Drug Design},
year = {2023},
volume = {102},
number = {5},
pages = {1085--1096},
doi = {10.1111/cbdd.14308}
}
EUVIMED